GHRH and GHRPs as Anti-Aging Therapeutics to Restore Declining Growth Hormone | Research

The takeaway

GHRH and GHRPs offer promising approaches to restore age-related GH decline, addressing the visceral fat accumulation and metabolic changes of GH deficiency in aging.

GH decline drives aging changes
Age-related GH decline contributes to visceral fat increase, muscle loss, and metabolic deterioration — all potentially addressable with secretagogues

What the researchers found

GHRH and GHRPs can restore GH secretion in aging and disease, addressing the visceral fat accumulation and metabolic changes associated with GH decline.

Why it matters

Age-related GH decline affects virtually everyone, contributing to body composition changes and metabolic deterioration. Secretagogue therapy offers a practical, physiological approach to restoring youthful GH levels.

How the study worked

Review chapter discussing the pathophysiology of GH decline and the therapeutic potential of GHRH and GHRPs across aging and disease states.

What this study cannot tell us

Review chapter; long-term safety of chronic GH stimulation in aging not fully established. Cancer risk with chronically elevated GH/IGF-1 is debated.

How to read the evidence

Moderate evidence from a comprehensive review covering aging, disease, and therapeutic applications of GH secretagogues.

When this study was published

Published in 1997, this review anticipated the current interest in peptide-based anti-aging interventions.

The bigger picture

This review positioned GH secretagogues as anti-aging therapeutics, anticipating the current interest in peptide-based approaches to healthy aging.

Questions still open

Is long-term GH secretagogue therapy safe for aging populations?
Which patients benefit most from GHRH vs. GHRP approaches?

Common questions

Why does GH decline with age?

Multiple factors: the hypothalamus produces less GHRH, somatostatin inhibition increases, body fat accumulation (which suppresses GH) increases, and IGF-1 feedback becomes more inhibitory. The result is a progressive decline in GH pulsatility.

Are GH secretagogues better than GH injections?

Potentially. Secretagogues preserve the body's natural pulsatile GH release pattern and are self-limiting (the pituitary can only release what it has). GH injections bypass this regulation and can cause more side effects at higher doses.

Read the original research

Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.

Recent progress in hormone research, 52, 215-44; discussion 244-6

View on PubMed ↗

Citation

Thorner, M O; Chapman, I M; Gaylinn, B D; Pezzoli, S S; Hartman, M L. (1997). Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.. Recent progress in hormone research, 52, 215-44; discussion 244-6.